Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology, and drug delivery markets. The Company"s platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.
Website: halozyme.com



Growth: Good revenue growth rate 22.1%, there is slowdown compared to average historical growth rates 49.5%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +39.2%. On average the margin is improving unsteadily. Gross margin is high, +84.4%. In the last quarter the company did not beat the estimated EPS, -2.1%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 130.7% higher than minimum and 10.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.5x by EV / Sales multiple , the company can be 17.6% undervalued

Insiders: For the last 3 months insiders sold company shares on $9.5 mln (-0.112% of cap.)

Key Financials (Download financials)

Ticker: HALO
Share price, USD:  (0.0%)69.87
year average price 63.81  


year start price 57.14 2025-02-08

min close price 47.91 2025-05-14

max close price 78.28 2025-09-22

current price 69.87 2026-02-07
Common stocks: 117 219 000

Dividend Yield:  0.0%
FCF Yield LTM: -0.6%
EV / LTM EBITDA: 12.0x
EV / EBITDA annualized: 10.2x
Last revenue growth (y/y):  +22.1%
Last growth of EBITDA (y/y):  +33.1%
Historical revenue growth:  +49.5%
Historical growth of EBITDA:  +37.5%
EV / Sales: 4.7x
Margin (EBITDA LTM / Revenue): 39.2%
Fundamental value created in LTM:
Market Cap ($m): 8 190
Net Debt ($m): 809
EV (Enterprise Value): 8 999
Price to Book: 16.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-04zacks.com

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

2026-02-02seekingalpha.com

Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth

2026-02-02zacks.com

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

2026-01-30zacks.com

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

2026-01-29zacks.com

HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance

2026-01-28seekingalpha.com

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript

2026-01-28prnewswire.com

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

2026-01-23defenseworld.net

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Moderate Buy” by Brokerages

2026-01-22newsfilecorp.com

Cleantek Industries Secures Significant International HALO SE Crown Mount Contract

2025-12-19zacks.com

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-03 2025-08-05 2024-10-31 2024-08-06 2024-05-07 2023-11-06 2023-08-08 2023-05-09 2022-11-08
acceptedDate 2025-10-03 16:51:54 2025-08-05 16:09:53 2025-02-18 16:17:19 2024-10-31 16:07:46 2024-08-06 16:07:29 2024-05-07 16:09:58 2024-02-20 16:07:29 2023-11-06 16:07:46 2023-08-08 16:10:02 2023-05-09 16:17:05 2023-02-21 16:27:38 2022-11-08 16:10:10 2022-02-22 16:21:55 2021-02-23 16:12:32
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 354M 326M 1 015M 290M 231M 196M 829M 216M 221M 162M 660M 209M 443M 268M
costOfRevenue 55M 46M 159M 49M 57M 46M 192M 55M 50M 35M 139M 47M 81M 43M
grossProfit 299M 279M 856M 241M 174M 150M 637M 161M 171M 127M 521M 162M 362M 224M
grossProfitRatio 0.844 0.858 0.83 0.752 0.765 0.746 0.773 0.783 0.774
researchAndDevelopmentExpenses 17M 18M 79M 18M 21M 19M 76M 17M 20M 18M 67M 17M 36M 34M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 46M 42M 154M 41M 36M 35M 149M 35M 39M 37M 144M 34M 50M 46M
otherExpenses 18M 18M 71M 18M 18M 18M 74M 20M 18M 18M 43M 27M 0 0
operatingExpenses 81M 77M 304M 77M 57M 54M 299M 73M 77M 73M 253M 78M 86M 80M
costAndExpenses 136M 123M 464M 127M 114M 100M 492M 128M 127M 108M 393M 126M 167M 123M
interestIncome 0 0 0 0 0 0 0 4M 0 0 0 0 0 0
interestExpense 4M 4M 18M 5M 5M 5M 19M 5M 4M 5M 17M 8M 8M 20M
depreciationAndAmortization 61M 21M 81M 20M 20M 20M 85M 20M 21M 18M 50M 29M 3M 3M
ebitda 285M 230M 657M 190M 138M 116M 452M 109M 115M 72M 316M 112M 259M 153M
ebitdaratio 0.803 0.706 0.655 0.595 0.591 0.503 0.521 0.442 0.538
operatingIncome 218M 202M 551M 163M 117M 96M 338M 88M 94M 54M 268M 83M 276M 144M
operatingIncomeRatio 0.615 0.622 0.563 0.507 0.488 0.409 0.427 0.332 0.399
totalOtherIncomeExpensesNet 1M 2M 6M 2M 508 000 486 000 11M 18M 3M -2M -19M -10M -27M -15M
incomeBeforeTax 219M 205M 557M 165M 118M 96M 348M 102M 93M 52M 249M 74M 249M 129M
incomeBeforeTaxRatio 0.618 0.629 0.569 0.509 0.49 0.471 0.421 0.322 0.353
incomeTaxExpense 44M 40M 113M 28M 24M 19M 67M 20M 18M 13M 47M 12M -154M 217 000
netIncome 175M 165M 444M 137M 93M 77M 282M 82M 75M 40M 202M 62M 403M 129M
netIncomeRatio 0.495 0.507 0.472 0.403 0.392 0.379 0.338 0.244 0.295
eps 1.49 1.36 3.5 1.08 0.73 0.61 2.13 0.62 0.57 0.29 1.48 0.45 2.86 0.95
epsdiluted 1.43 1.33 1.05 0.72 0.6 0.61 0.56 0.29 0.44
weightedAverageShsOut 117M 121M 127M 127M 127M 127M 132M 132M 132M 135M 137M 137M 141M 136M
weightedAverageShsOutDil 122M 124M 129M 130M 129M 129M 134M 134M 134M 138M 141M 139M 147M 141M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-22 2021-02-23
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -18M -19M -17M -8M -20M
ebit 575M 367M 266M 256M 150M
nonOperatingIncomeExcludingInterest -24M -30M 2M 20M -5M
netIncomeFromContinuingOperations 444M 282M 202M 403M 129M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 444M 282M 202M 403M 129M
epsDiluted 3.43 2.1 1.44 2.74 0.91

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-03 2025-08-05 2024-10-31 2024-08-06 2024-05-07 2023-11-06 2023-08-08 2023-05-09 2022-11-08
acceptedDate 2025-10-03 16:51:54 2025-08-05 16:09:53 2025-02-18 16:17:19 2024-10-31 16:07:46 2024-08-06 16:07:29 2024-05-07 16:09:58 2024-02-20 16:07:29 2023-11-06 16:07:46 2023-08-08 16:10:02 2023-05-09 16:17:05 2023-02-21 16:27:38 2022-11-08 16:10:10 2022-02-22 16:21:55 2021-02-23 16:12:32
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 420M 62M 116M 154M 188M 165M 118M 274M 221M 96M 234M 147M 119M 148M
shortTermInvestments 282M 486M 480M 512M 341M 299M 218M 209M 127M 179M 129M 118M 622M 220M
cashAndShortTermInvestments 702M 548M 596M 666M 529M 463M 336M 483M 348M 276M 363M 266M 741M 368M
netReceivables 346M 316M 308M 286M 215M 196M 234M 217M 246M 195M 231M 233M 91M 98M
inventory 186M 182M 142M 131M 159M 169M 128M 129M 132M 108M 100M 103M 54M 61M
otherCurrentAssets 95M 77M 39M 44M 85M 46M 49M 49M 39M 37M 45M 51M 0 0
totalCurrentAssets 1 329M 1 123M 1 085M 1 127M 988M 874M 746M 879M 766M 615M 739M 653M 926M 555M
propertyPlantEquipmentNet 71M 72M 75M 74M 75M 78M 75M 75M 75M 78M 76M 37M 9M 11M
goodwill 417M 417M 417M 417M 417M 417M 417M 417M 417M 416M 409M 199M 0 0
intangibleAssets 349M 366M 402M 420M 437M 455M 473M 491M 511M 529M 547M 949M 0 0
goodwillAndIntangibleAssets 765M 783M 819M 836M 854M 872M 890M 907M 928M 945M 956M 1 148M 0 0
longTermInvestments 0 0 0 0 200 000 300 000 0 0 0 0 0 0 0 0
taxAssets 0 20M 4M 0 0 616 000 4M 13M 24M 36M 44M 0 155M 0
otherNonCurrentAssets 56M 56M 81M 80M 52M 17M 18M 18M 18M 26M 27M 26M 14M 15M
totalNonCurrentAssets 892M 931M 978M 991M 982M 968M 987M 1 014M 1 045M 1 084M 1 102M 1 211M 178M 25M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 2 221M 2 054M 2 063M 2 118M 1 969M 1 842M 1 733M 1 893M 1 810M 1 699M 1 842M 1 865M 1 104M 580M
accountPayables 15M 19M 10M 12M 15M 13M 12M 19M 10M 9M 18M 18M 2M 2M
shortTermDebt 711M 0 0 0 0 32M 0 32M 0 0 13M 13M 89M 397M
taxPayables 0 0 0 0 29M 19M 963 000 18M 0 0 0 0 0 0
deferredRevenue 0 0 0 0 29M 19M 0 667 000 842 000 3M 3M 4M 2M 2M
otherCurrentLiabilities 111M 116M 0 96M 89M 67M 0 63M 105M 80M -3M 74M 0 0
totalCurrentLiabilities 837M 134M 139M 109M 133M 132M 112M 115M 116M 92M 131M 109M 117M 421M
longTermDebt 800M 1 509M 1 506M 1 504M 1 533M 1 501M 1 499M 1 498M 1 496M 1 494M 1 493M 1 491M 787M 0
deferredRevenueNonCurrent 0 0 0 0 -1 0 0 2M 2M 2M 2M 3M 3M 4M
deferredTaxLiabilitiesNonCurrent 8M 0 0 12M 14M 0 0 0 0 0 0 29M 0 0
otherNonCurrentLiabilities 72M 78M 55M 40M 0 31M 38M 28M 45M 45M 46M 1 623M 544 000 3M
totalNonCurrentLiabilities 880M 1 587M 1 561M 1 557M 1 547M 1 532M 1 537M 1 528M 1 543M 1 542M 1 541M 1 658M 790M 7M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 31M 32M 0 32M 0 0 0 0 0 0
totalLiabilities 1 717M 1 721M 1 700M 1 665M 1 680M 1 664M 1 649M 1 643M 1 659M 1 634M 1 672M 1 768M 907M 429M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 118 000 118 000 123 000 127 000 127 000 127 000 127 000 132 000 132 000 132 000 135 000 135 000 138 000 135 000
retainedEarnings 502M 361M 360M 398M 261M 167M 91M 222M 140M 66M 143M 86M -59M -475M
accumulatedOtherComprehensiveIncomeLoss -22M -28M 4M -7M -2M -1M -9M 1M -2M 24 000 -922 000 -2M -620 000 22 000
othertotalStockholdersEquity 24M 0 62M 31M 12M 26M 12M 0 13M
totalStockholdersEquity 504M 333M 364M 453M 289M 178M 84M 249M 151M 66M 170M 97M 197M 151M
totalEquity 504M 333M 364M 453M 289M 178M 84M 249M 151M 66M 170M 97M 197M 151M
totalLiabilitiesAndStockholdersEquity 2 221M 2 054M 2 118M 1 969M 1 842M 1 893M 1 810M 1 699M 1 865M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 2 221M 2 054M 2 063M 2 118M 1 969M 1 842M 1 733M 1 893M 1 810M 1 699M 1 842M 1 865M 1 104M 580M
totalInvestments 282M 486M 480M 512M 341M 299M 218M 209M 127M 179M 129M 118M 622M 220M
totalDebt 1 511M 1 509M 1 506M 1 504M 1 533M 1 533M 1 499M 1 498M 1 496M 1 494M 1 506M 1 504M 877M 397M
netDebt 1 091M 1 447M 1 390M 1 350M 1 345M 1 368M 1 381M 1 223M 1 275M 1 398M 1 272M 1 357M 758M 250M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-22 2021-02-23
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 308M 234M 231M 91M 98M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 40M 28M
totalPayables 10M 12M 18M 2M 2M
otherPayables 0 0 0 0 0
accruedExpenses 129M 101M 100M 24M 20M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 2M 27M 256M 625M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO HALO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-03 2025-08-05 2024-10-31 2024-08-06 2024-05-07 2023-11-06 2023-08-08 2023-05-09 2022-11-08
acceptedDate 2025-10-03 16:51:54 2025-08-05 16:09:53 2025-02-18 16:17:19 2024-10-31 16:07:46 2024-08-06 16:07:29 2024-05-07 16:09:58 2024-02-20 16:07:29 2023-11-06 16:07:46 2023-08-08 16:10:02 2023-05-09 16:17:05 2023-02-21 16:27:38 2022-11-08 16:10:10 2022-02-22 16:21:55 2021-02-23 16:12:32
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 175M 165M 444M 137M 93M 77M 282M 82M 75M 40M 202M 62M 403M 129M
depreciationAndAmortization 22M 22M 89M 20M 20M 20M 85M 23M 21M 20M 57M 29M 7M 17M
deferredIncomeTax 0 0 0 292 000 14M 1M 35M 10M 12M 4M 0 26M 0 0
stockBasedCompensation 12M 12M 43M 13M 9M 10M 37M 9M 10M 8M 24M 7M 21M 17M
changeInWorkingCapital -51M -62M -136M -54M -82M 22M -39M 22M -48M 14M -110M -60M 3M -67M
accountsReceivables -30M -12M -74M -71M -19M 38M -3M 29M -51M 36M -84M -44M 7M -38M
inventory -1M -15M -67M 2M -21M -40M -27M 4M -25M -7M -17M -6M 7M -31M
accountsPayables 0 0 0 -22M 0 19M -13M 0 0 -24M 0 0 0 0
otherWorkingCapital -20M -36M 5M 37M -42M 23M 4M -10M 28M -5M -9M -10M -12M 3M
otherNonCashItems 20M -38M 39M -926 000 91M 52M -10M -14M -1M 1M 67M 6M -133M -41M
netCashProvidedByOperatingActivities 179M 100M 479M 115M 56M 129M 389M 132M 67M 87M 240M 70M 299M 55M
investmentsInPropertyPlantAndEquipment -3M -2M -11M -2M -3M -4M -15M -3M 2M -11M -5M -1M -1M -3M
acquisitionsNet 0 0 0 0 0 0 0 81M 0 0 -999M 0 0 0
purchasesOfInvestments 0 0 0 -304M -93M -199M -293M -162M 0 -110M 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 138M 54M 120M 211M 81M 53M 61M 0 0 0 0
otherInvestingActivites 205M 86M 0 -39M -79M -81M 0 0 0
netCashUsedForInvestingActivites 202M 85M -167M -42M -83M -83M 55M -60M -1M
debtRepayment 0 0 0 0 0 0 0 -13M -447M
commonStockIssued 0 0 19M 9M -489 000 4M 0 -1M 0
commonStockRepurchased -39M -300M -250M 0 0 -489 000 -402M 0 0 -150M -200M -200M -350M -150M
dividendsPaid 0 0 0 0 0 0 0 -13M 0
otherFinancingActivites 16M 1M 0 9M -489 000 4M 0 13M 635M
netCashUsedProvidedByFinancingActivities -22M -299M 19M 9M -489 000 4M 2M -165M -12M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 358M -114M -3M -34M 23M 46M -116M 53M 124M -138M 115M 56M -29M 28M
cashAtEndOfPeriod 420M 62M 116M 154M 188M 165M 118M 274M 221M 97M 235M 148M 119M 148M
cashAtBeginningOfPeriod 62M 176M 118M 188M 165M 118M 235M 221M 97M 235M 119M 91M 148M 121M
operatingCashFlow 179M 100M 479M 115M 56M 129M 389M 132M 67M 87M 240M 70M 299M 55M
capitalExpenditure -3M -2M -11M -2M -3M -4M -15M -3M 2M -11M -5M -1M -1M -3M
freeCashFlow 176M 98M 468M 114M 53M 126M 373M 129M 68M 76M 235M 69M 298M 53M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-18 2024-02-20 2023-02-21 2022-02-22 2021-02-23
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -252M 0 517M -405M 81M
netCashProvidedByInvestingActivities -263M -97M -487M -406M 78M
netDebtIssuance 0 -13M 625M 416M -20M
longTermNetDebtIssuance 0 -13M 625M 416M -20M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -250M -402M -200M -350M -150M
netCommonStockIssuance -250M -402M -200M -350M -150M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 31M 8M -62M 12M 63M
netCashProvidedByFinancingActivities -219M -408M 362M 78M -106M
incomeTaxesPaid 0 32M 0 0 0
interestPaid 11M 11M 6M 3M 7M

Earning call transcript

2025 q3
2025-11-03 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q4
2025-02-18 ET (fiscal 2024 q4)
2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-20 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-21 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-03 16:13 ET
Halozyme Therapeutics reported for 2025 q3
SEC form 8
2025-11-03 16:07 ET
Halozyme Therapeutics published news for 2025 q3
SEC form 8
2025-11-03 16:07 ET
Halozyme Therapeutics reported for 2025 q3
SEC form 10
2025-08-05 20:09 ET
Halozyme Therapeutics published news for 2025 q2
SEC form 8
2025-08-05 20:06 ET
Halozyme Therapeutics published news for 2025 q2
SEC form 8
2025-08-05 20:06 ET
Halozyme Therapeutics reported for 2025 q2
SEC form 10
2025-05-06 20:08 ET
Halozyme Therapeutics published news for 2025 q1
SEC form 8
2025-05-06 20:06 ET
Halozyme Therapeutics published news for 2025 q1
SEC form 8
2025-05-06 20:06 ET
Halozyme Therapeutics reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Halozyme Therapeutics published news for 2025 q1
SEC form 10
2025-02-18 21:17 ET
Halozyme Therapeutics published news for 2024 q4
SEC form 10
2025-02-18 00:00 ET
Halozyme Therapeutics reported for 2024 q4
SEC form 8
2025-02-18 00:00 ET
Halozyme Therapeutics published news for 2024 q4
SEC form 8
2025-02-18 00:00 ET
Halozyme Therapeutics published news for 2024 q4
SEC form 8
2025-01-08 00:00 ET
Halozyme Therapeutics published news for 2024 q4
SEC form 8
2025-01-08 00:00 ET
Halozyme Therapeutics reported for 2024 q4
SEC form 10
2024-10-31 16:07 ET
Halozyme Therapeutics published news for 2024 q3
SEC form 8
2024-10-31 16:05 ET
Halozyme Therapeutics published news for 2024 q3
SEC form 8
2024-10-31 16:05 ET
Halozyme Therapeutics reported for 2024 q3
SEC form 10
2024-08-06 16:07 ET
Halozyme Therapeutics published news for 2024 q2
SEC form 8
2024-08-06 16:03 ET
Halozyme Therapeutics published news for 2024 q2
SEC form 8
2024-08-06 16:03 ET
Halozyme Therapeutics reported for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Halozyme Therapeutics published news for 2024 q2
SEC form 10
2024-05-07 16:09 ET
Halozyme Therapeutics reported for 2024 q1
SEC form 8
2024-05-07 16:05 ET
Halozyme Therapeutics published news for 2024 q1
SEC form 8
2024-05-07 16:05 ET
Halozyme Therapeutics published news for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Halozyme Therapeutics published news for 2024 q1
SEC form 10
2024-02-20 16:07 ET
Halozyme Therapeutics reported for 2023 q4
SEC form 8
2024-02-20 16:03 ET
Halozyme Therapeutics published news for 2023 q4
SEC form 8
2024-02-20 16:03 ET
Halozyme Therapeutics published news for 2023 q4
SEC form 10
2024-02-20 00:00 ET
Halozyme Therapeutics published news for 2023 q4
SEC form 8
2024-01-17 00:00 ET
Halozyme Therapeutics published news for 2023 q4
SEC form 10
2023-11-06 16:07 ET
Halozyme Therapeutics reported for 2023 q3
SEC form 8
2023-11-06 16:04 ET
Halozyme Therapeutics published news for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Halozyme Therapeutics published news for 2023 q3
SEC form 10
2023-08-08 16:10 ET
Halozyme Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:06 ET
Halozyme Therapeutics published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Halozyme Therapeutics published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Halozyme Therapeutics published news for 2023 q2
SEC form 10
2023-05-09 00:00 ET
Halozyme Therapeutics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Halozyme Therapeutics published news for 2023 q1
SEC form 6
2023-03-15 18:28 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 6
2023-03-13 08:47 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 6
2023-02-23 16:05 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 10
2023-02-21 16:27 ET
Halozyme Therapeutics reported for 2022 q4
SEC form 6
2023-02-21 16:21 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 10
2023-02-21 00:00 ET
Halozyme Therapeutics reported for 2022 q4
SEC form 8
2023-02-21 00:00 ET
Halozyme Therapeutics reported for 2022 q4
SEC form 6
2023-02-06 17:19 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 6
2023-02-06 16:03 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 6
2023-01-10 17:16 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 8
2023-01-10 00:00 ET
Halozyme Therapeutics published news for 2022 q4
SEC form 10
2022-11-08 16:10 ET
Halozyme Therapeutics reported for 2022 q3
SEC form 6
2022-11-08 16:06 ET
Halozyme Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Halozyme Therapeutics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Halozyme Therapeutics reported for 2022 q3
SEC form 6
2022-08-19 17:23 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 6
2022-08-18 17:14 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 6
2022-08-16 08:42 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 6
2022-08-15 07:18 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 6
2022-08-09 16:13 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 16:12 ET
Halozyme Therapeutics reported for 2022 q2
SEC form 6
2022-08-09 16:08 ET
Halozyme Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Halozyme Therapeutics reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Halozyme Therapeutics reported for 2022 q2
SEC form 6
2022-05-24 16:16 ET
Halozyme Therapeutics published news for 2022 q1
SEC form 10
2022-05-10 16:15 ET
Halozyme Therapeutics reported for 2022 q1
SEC form 6
2022-05-10 16:07 ET
Halozyme Therapeutics published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Halozyme Therapeutics reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Halozyme Therapeutics reported for 2022 q1
SEC form 6
2022-05-06 16:10 ET
Halozyme Therapeutics published news for 2022 q1
SEC form 6
2022-04-13 17:18 ET
Halozyme Therapeutics published news for 2022 q1
SEC form 6
2022-03-25 16:31 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2022-03-21 16:11 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2022-03-15 16:50 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 10
2022-02-22 16:21 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2022-02-22 16:06 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 10
2022-02-22 00:00 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 8
2022-02-22 00:00 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2022-02-03 16:12 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 08:12 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Halozyme Therapeutics published news for 2021 q4
SEC form 6
2021-12-29 16:15 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 6
2021-12-13 17:10 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 6
2021-12-10 16:08 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 6
2021-11-02 17:03 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 16:09 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 6
2021-11-02 16:03 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Halozyme Therapeutics published news for 2021 q3
SEC form 10
2021-08-09 16:07 ET
Halozyme Therapeutics published news for 2021 q2
SEC form 6
2021-08-09 16:02 ET
Halozyme Therapeutics published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Halozyme Therapeutics published news for 2021 q2
SEC form 8
2021-08-09 00:00 ET
Halozyme Therapeutics published news for 2021 q2
SEC form 10
2021-05-10 16:08 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 6
2021-05-10 16:03 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 6
2021-05-07 16:31 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 6
2021-05-05 16:01 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 6
2021-05-03 16:03 ET
Halozyme Therapeutics published news for 2021 q1
SEC form 6
2021-03-26 16:04 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-03-01 16:06 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-02-25 06:06 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-02-23 16:16 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 10
2021-02-23 16:12 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-02-23 16:03 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-01-13 17:11 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 08:07 ET
Halozyme Therapeutics published news for 2020 q4
SEC form 10
2020-11-02 16:11 ET
Halozyme Therapeutics published news for 2020 q3
SEC form 6
2020-11-02 16:04 ET
Halozyme Therapeutics published news for 2020 q3